Pharmaceuticals Japan

Japan Overactive Bladder Treatment Market Analysis, 2024–2034

Japan Overactive Bladder Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $262.3 Mn Estimated value
Estimate 2025 $273.1 Mn 5.6% of the global market
Projected 2034 $392.1 Mn 43.6% Adds $119.0 Mn over 9 forecast years
CAGR 2025–2034 4.1% Faster than 4% of 180 Pharmaceuticals markets here
Key players 5
  • Japan is 5.61% of the global market.
  • In APAC, the largest is China at $376.8 Mn.
  • Fastest growing: India at 7.1% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$119.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Overactive Bladder Treatment Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $262.3 Mn — —
2025 (base) $273.1 Mn +$10.8 Mn —
2026 (forecast) $284.3 Mn +$11.2 Mn +4.1%
2027 (forecast) $295.9 Mn +$11.7 Mn +8.4%
2028 (forecast) $308.1 Mn +$12.1 Mn +12.8%
2029 (forecast) $320.7 Mn +$12.6 Mn +17.4%
2030 (forecast) $333.9 Mn +$13.1 Mn +22.3%
2031 (forecast) $347.5 Mn +$13.7 Mn +27.3%
2032 (forecast) $361.8 Mn +$14.2 Mn +32.5%
2033 (forecast) $376.6 Mn +$14.8 Mn +37.9%
2034 (forecast) $392.1 Mn +$15.4 Mn +43.6%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $4.87 Bn
  2. North America $2.61 Bn
  3. US $2.01 Bn
  4. APAC $1.11 Bn
  5. Europe $934.0 Mn
  6. China $376.8 Mn
  7. Canada $353.4 Mn
  8. Japan (this report) $273.1 Mn
  9. Latin America $250.2 Mn
  10. Middle East $203.5 Mn
  11. Germany $171.3 Mn
  12. Brazil $135.3 Mn
  13. France $130.3 Mn
  14. UK $126.3 Mn
  15. Italy $122.0 Mn
  16. Ecuador $104.8 Mn
  17. Spain $92.7 Mn
  18. India $90.3 Mn
  19. Saudi Arabia $81.7 Mn
  20. Africa $80.9 Mn
  21. Mexico $73.0 Mn
  22. Australia $63.0 Mn
  23. New Zealand $53.9 Mn
  24. Russia $48.8 Mn
  25. South Africa $36.4 Mn
  26. UAE $27.5 Mn
  27. Egypt $14.1 Mn
  28. Philippines $11.8 Mn
  29. Malaysia $9.0 Mn
  30. Hong Kong $8.0 Mn
  31. Thailand $6.4 Mn
  32. Singapore $6.0 Mn
  33. Kenya $3.2 Mn

The Japan Overactive Bladder Treatment Market Analysis Executive Summary

Overactive bladder treatments reduce sudden urges and frequent urination with medicines, Botox and nerve stimulation.

Key segments of the overactive Bladder Treatment market include treatment (Anticholinergics, Beta-3 Agonists and Botulinum Toxin) and age (Adults and Older Adults).

Japan Overactive Bladder Treatment Market Dynamics

Market Growth Drivers

An ageing male population, more men seeking care, less invasive procedures and telehealth for sensitive conditions are driving the overactive Bladder Treatment market.

Opportunity

Office-based procedures, direct-to-consumer telehealth and wider insurance coverage give the overactive Bladder Treatment market room to grow.

Market Restraints

Stigma, out-of-pocket costs and limited reimbursement for some procedures hold back the overactive Bladder Treatment market.

Competitive Landscape for Overactive Bladder Treatment Market in Japan

The overactive Bladder Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Overactive Bladder Treatment Market in Japan

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for overactive Bladder Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Overactive Bladder Treatment right now, from free public sources.

Latest research 39 papers since 2021 (worldwide)

  1. Global Research Trends in Pediatric Lower Urinary Tract Dysfunction: A Bibliometric Analysis (1945-2026). Healthcare (Basel, Switzerland), 2026
  2. Why Do Clinically Ideal Sacral Nerve Stimulator Candidates Choose Botulinum Toxin Instead? A Study of Advanced Overactive Bladder Treatment Decision-Making. Neurourology and urodynamics, 2026
  3. The Benefits of Adding Non-Antimuscarinic Pharmaceuticals in Combination With Beta-3 Agonists for Overactive Bladder Treatment: A Systematic Review. Neurourology and urodynamics, 2026
  4. Sex- and Age-Specific Trends in Prescriptions of Beta-3 Agonists and Anticholinergics in Japan: A Nationwide Prescription Database Study. Lower urinary tract symptoms, 2026
  5. Age and Urinary Retention in Women After Botox Treatment for Overactive Bladder. Urogynecology (Philadelphia, Pa.), 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Overactive Bladder Treatment in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How much research is published on Overactive Bladder Treatment?
PubMed lists 39 papers added since January 2021 that match this market, worldwide.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Overactive Bladder Treatment in Japan? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Bone and Joint Health: Supplements for an Ageing Population1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence… Eye Health Supplements: Screens, Ageing and Vision2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a… Collagen Supplements: Skin, Joints and Real EvidenceCollagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Japan

See all
Same topic, other categories

Related on kidney health and geriatric

See the topic